KR20230157354A - 치료 방법 - Google Patents

치료 방법 Download PDF

Info

Publication number
KR20230157354A
KR20230157354A KR1020237031649A KR20237031649A KR20230157354A KR 20230157354 A KR20230157354 A KR 20230157354A KR 1020237031649 A KR1020237031649 A KR 1020237031649A KR 20237031649 A KR20237031649 A KR 20237031649A KR 20230157354 A KR20230157354 A KR 20230157354A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
subject
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237031649A
Other languages
English (en)
Korean (ko)
Inventor
배리 에스. 콜러
씨. 마이클 깁슨
아노우드 더블유.제이. 반'트 호프
Original Assignee
셀레코어 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀레코어 테라퓨틱스, 인크. filed Critical 셀레코어 테라퓨틱스, 인크.
Publication of KR20230157354A publication Critical patent/KR20230157354A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237031649A 2021-02-17 2022-02-16 치료 방법 Pending KR20230157354A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150301P 2021-02-17 2021-02-17
US63/150,301 2021-02-17
PCT/US2022/016571 WO2022177968A1 (en) 2021-02-17 2022-02-16 Therapeutic methods

Publications (1)

Publication Number Publication Date
KR20230157354A true KR20230157354A (ko) 2023-11-16

Family

ID=82931154

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237031649A Pending KR20230157354A (ko) 2021-02-17 2022-02-16 치료 방법

Country Status (10)

Country Link
US (1) US20250268902A1 (https=)
EP (1) EP4294402A4 (https=)
JP (1) JP2024507294A (https=)
KR (1) KR20230157354A (https=)
CN (1) CN117098538A (https=)
AU (1) AU2022224562A1 (https=)
BR (1) BR112023016459A2 (https=)
CA (1) CA3211215A1 (https=)
MX (1) MX2023009620A (https=)
WO (1) WO2022177968A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019771A1 (en) * 2024-07-15 2026-01-22 Celecor Therapeutics, Inc. Zalunfiban for use in the treatment of thrombotic disorder in patients with renal impairment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2804610B1 (en) * 2012-01-16 2018-10-31 The Rockefeller University Organic compounds
US11684622B2 (en) * 2018-06-19 2023-06-27 Celecor Therapeutics, Inc. Deuterated RUC-4

Also Published As

Publication number Publication date
WO2022177968A1 (en) 2022-08-25
EP4294402A4 (en) 2025-01-15
MX2023009620A (es) 2023-11-01
WO2022177968A9 (en) 2022-10-20
EP4294402A1 (en) 2023-12-27
JP2024507294A (ja) 2024-02-16
CA3211215A1 (en) 2022-08-25
CN117098538A (zh) 2023-11-21
BR112023016459A2 (pt) 2023-10-10
AU2022224562A1 (en) 2023-08-31
WO2022177968A8 (en) 2022-11-17
US20250268902A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
Jackson et al. Effects of sildenafil citrate on human hemodynamics
Raymond et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma
DE60316798T2 (de) Zusammensetzungen und verfahren zur behandlung von diabetes
AU2012321106C1 (en) Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent
Hase et al. Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia
Chung et al. Inhibition of Fas signaling prevents hepatic injury and improves organ blood flow during sepsis
RS58750B1 (sr) Kombinovane formulacije neosaksitoksina za produženu lokalnu anesteziju
AU2005295437B2 (en) Use of A2A adenosine receptor agonists
US20140314676A1 (en) Methods of treatment with deferiprone
KR101951220B1 (ko) 조합 als 치료법
JP2023052576A (ja) Ｐ２ｙ１２受容体アンタゴニストの皮下投与
US20220073888A1 (en) Combination treatment
KR20230157354A (ko) 치료 방법
KR20200076705A (ko) 둘라글루티드를 함유하는 조성물 및 사용 방법
JP2014505106A (ja) 肺高血圧症を処置するための方法
Barrett et al. Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers
KR20220063157A (ko) 빌다글립틴 및 메트포르민을 이용한 조합 요법
JP2024507294A5 (https=)
US20260115210A1 (en) Method for treating subjects suffering from central nervous system contusions
Santos et al. The maternal and fetal effects of milrinone and dopamine in normotensive pregnant ewes
WO2026019771A1 (en) Zalunfiban for use in the treatment of thrombotic disorder in patients with renal impairment
Ghodrati et al. Antinociceptive effects of fentanyl and nonopioid drugs in methocinnamox-treated rats
KR20210014024A (ko) 트리사이클릭 유도체를 이용한 뇌졸중의 치료 방법
Zhao et al. Ranolazine, a novel anti-anginal agent, does not alter isosorbide dinitrate-or sildenafil-induced changes in blood pressure in conscious dogs
CN121772919A (zh) 用于达到mTOR抑制剂的有效剂量水平的组合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230915

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250214

Comment text: Request for Examination of Application